Income Statement | 2025-06-30 | |||
---|---|---|---|---|
Research and development | 4,299,941 | |||
General and administrative | 4,923,540 | |||
Total operating expenses | -9,223,481 | |||
Loss from operations | -9,223,481 | |||
Other | -1,195 | |||
Interest income | 257,913 | |||
Interest expense | -382,014 | |||
Grant income | 864,014 | |||
Other income, net | 738,718 | |||
Net loss | -8,484,763 | |||
Net loss per share, basic | -0.25 | |||
Net loss per share, diluted | -0.25 | |||
Weighted average common shares outstanding, basic | 33,820,306 | |||
Weighted average common shares outstanding, diluted | 33,820,306 |
Anebulo Pharmaceuticals, Inc. (ANEB)
Anebulo Pharmaceuticals, Inc. (ANEB)